In some salivary duct carcinomas, like breast cancers, the expressions of androgen receptor (AR) or human epidermal growth factor 2 (HER2) were observed to be positive, and AR-targeted hormonal therapy and a HER2-targeted antibody showed high response rates [82, 83]. This evidence concerns the gene ERBB2 and breast cancer.